Background: Immunosuppressed (IS) patients, particularly solid organ transplant recipients and those on immunosuppressive therapy, face a higher incidence and recurrence of nonmelanoma skin cancers (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Mohs micrographic surgery (MMS) is the preferred treatment for high-risk NMSC due to its high cure rate and margin examination capabilities. However, IS patients may experience more complications, such as surgical site infections, and a greater risk of recurrence, making their outcomes a subject of interest.
View Article and Find Full Text PDFActas Dermosifiliogr
June 2024
Objective: The aim of our research was to compare the evolution of the immune response induced by the BNT162b2 vaccine after the administration of two and three doses in healthcare personnel and in institutionalized elderly people (>65 years of age) without previous SARS-CoV-2 infection.
Material And Methods: A prospective observational study was carried out on a convenience sample made up of health workers and institutionalized elderly people, measuring antibodies against S and N proteins of SARS-CoV-2 two and six months after receiving the second vaccine dose, as well as two months after receiving the third dose.
Results: A significant reduction of the anti-S humoral immune response was reported six months after the second dose of vaccine in both health workers and residents.
A 91-year-old man presented with pruriginous tense blisters and erosions on the upper and lower extremities (Figures 1A and 1B). Mucous membranes were unaffected and Nikolsky's sign was negative. These lesions appeared 48 hours after the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine.
View Article and Find Full Text PDF